RHY 0.00% 4.7¢ rhythm biosciences limited

Bescreened 10,000 patient tests /trial, page-18

  1. 280 Posts.
    lightbulb Created with Sketch. 95
    if Bescreened can manage to sell tests on the strength of a single dodgy tiny clinical trial and a few misleading investor presentations, all whilst their panel of bio markers relies on CEA, widely agreed to be unsuitable for population screening... then, actually, I'm feeling even more positive about Colostat's potential than I was before!
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.